Site Search     
  A Systems Biology Approach for Pediatric and Adult Autoimmune Diseases
 

Genome-Wide Profiling of Antigen-Specific Immunoreactivity in Multiple Sclerosis (A Pilot Project to ‘A Systems Biology Approach for Pediatric and Adult Autoimmune Diseases’; PI: Virginia Pascual, MD)

  A Systems Biology Approach to Islet Antigen Immunoreactivity Profiling in T1D
  Altered CD8+ T Cell Compartment in SLE Patients
  Blood Transcriptional Biomarker Profiles for Category B Pathogens
  Center for Lupus Research
  Diversification of cytotoxic effector cells via LPS-activated DCs
  Harnessing Human DC Subsets for Improved Mucosal Vaccines
 

Supplement #1 to ‘Harnessing Human DC Subsets for Improved Mucosal Vaccines’

 

Supplement #2 to ‘Harnessing Human DC Subsets for Improved Mucosal Vaccines’

 

Supplement #3 to ‘Harnessing Human DC Subsets for Improved Mucosal Vaccines’

  Immunotherapeutic HPV Cancer Vaccines that Target Langerhans Cells
  Improving the Efficacy of Dendritic Cell Vaccines
  Monitoring Blood Genome Activity during Pregnancy
  Novel Dendritic Cell-Based HIV Vaccines
  Towards an HCV Vaccine
  Transcriptional Signatures for Diagnosis of Different Spectra of Mycobacterium tuberculosis Infection and Characterization of the Immune Response during Latency or Active Disease
arrow Use of Microarrays to Understand Systemic Arthritis
  Vaccination with IL-15 DC to Generate Melanoma-Specific Protective Memory T Cells
Use of Microarrays to Understand Systemic Arthritis
Grant Number: 5R01AR050770-02
PI: Virginia Pascual, MD.
Funding Organization: National Institute of Arthritis and Musculoskeletal and Skin
Project Start: September 22, 2003
Project End: May 31, 2013

Abstract:

Systemic Onset Juvenile Chronic Arthritis (SOJCA) is a disease that carries severe long-term disability for 50% of the children who suffer from it. The pathogenesis of this disease remains a mystery and there are no animal models to reproduce it. As opposed to other forms of Juvenile Chronic Arthritis, no serologic markers like autoantibodies, HLA associations, or other specific diagnostic tests are available. We now have preliminary data showing significant alterations in the blood mononuclear cells from SOJCA patients, including 1) increased numbers of blood monocytes with an activated phenotype, 2) a gene signature shared with patients with bacterial infections, 3) a unique gene signature. The present proposal aims at further strengthening these data through the accrual of a larger number of patients and the analyses of a larger selection of genes. We expect that these studies will provide us with clues to understand the pathogenesis of the disease. We are particularly intrigued by the similarities observed between SOJCA and systemic infections especially with those caused by Staphylococcus aureus. We propose to correlate the SOJCA genetic signature with the outcome of the disease. In particular, the four-year proposed study will permit us to compare the gene profiles of patients who get disease resolution from those who develop a chronic, highly debilitating disease. In vitro studies are designed to eventually identify the cellular and molecular mechanisms leading to the SOJCA signature, thereby allowing us to better understand the disease. Our ultimate goal is to design novel therapies to antagonize the causative agent and/or the genetic pathways responsible for the establishment of this intriguing disease.